New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
05:37 EDTILMNIllumina upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Illumina after its channel checks indicated the company is experiencing next-gen sequencing share gains. The firm raised its price target for shares to $61 from $47.
News For ILMN From The Last 14 Days
Check below for free stories on ILMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
05:42 EDTILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
10:04 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTILMNIllumina upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use